Clifford A. Hudis, MD: Are Cancer Drug Prices in the U.S. the Problem or the Symptom?

First International Summit on Interventional Pharmacoeconomics

Blase N. Polite, MD, MPP, on Optimizing Cancer Policies in the United States

Blase N. Polite, MD, MPP, of the University of Chicago Medical Center, discusses his belief that, in the next few years, we can bend the cancer drug cost curve and tame health-care costs if physicians, pharmaceutical companies, payers, and government come together and agree on the value of treatments that improve survival and quality of life.

Daniel Goldstein, MD: Interventional Pharmacoeconomics - Why and How

Javid J. Moslehi, MD, on Cardiovascular and Thrombotic Considerations of Kinase Inhibitors: The Case of BTK Inhibitors

The Interventional Pharmacoeconomic Toolbox Panel Discussion

Opening Session Panel Discussion

Oct

Today In Oncology

Clifford A. Hudis, MD: Are Cancer Drug Prices in the U.S. the Problem or the Symptom?

Related Videos

Blase N. Polite, MD, MPP, on Optimizing Cancer Policies in the United States

Daniel Goldstein, MD: Interventional Pharmacoeconomics - Why and How

Javid J. Moslehi, MD, on Cardiovascular and Thrombotic Considerations of Kinase Inhibitors: The Case of BTK Inhibitors

The Interventional Pharmacoeconomic Toolbox Panel Discussion

Opening Session Panel Discussion

Impact of Proton and Photon Therapy on HRQOL in Breast Cancer

Older Women With High-Risk Breast Cancer Addition of Adjuvant Chemotherapy to Hormone Therapy

Study Shows That After Early Breast Cancer Diagnosis, Risk of a Second Cancer is Low

Advanced or Metastatic Breast Cancer: FDA Approves Imlunestrant for ER-Positive, HER2-Negative, ESR1-Mutated Disease

Use of Obecabtagene Autoleucel CAR T-Cell Therapy for B-Cell Acute Lymphocytic Leukemia